Assessment of Antioxidant Status and Ceruloplasmin in Early and Advanced Stages of Sporadic Colorectal Cancer Patients whom Receiving Adjuvant Chemotherapy

Abstract

One of most frequent malignant disease in the developed countries is colorectal cancer and it is the seventh most common cancers among population of Babylon province/Iraq. It was reported that oxidative stress status is being play a very important roles in development of carcinogenesis. The purpose from this study was assessment of antioxidant status in early and advanced stages of patients with sporadic colorectal cancer whom received adjuvant chemotherapy. This investigate was done by measuring of total antioxidant capacity(TAO-C), Ceruloplasmin and its related trace elements ,copper and Zink. All patients included in this study were receiving adjuvant chemotherapy regimen and subdivided into two groups according to Duke´s classification of malignant into early stages (A+B) and(C+D) advanced stages, cancer site (colon and rectum), and according to the number of dosage of chemotherapy regimen(half dosage and total dosage). ELISA methods were used to assess serum Cp concentration and colorimetric method for measurement of serum TAO-C ,while concentration of Cu and Zn were determined by atomic absorption spectrophotometer ( AAS). Cu/Zn and Cu/Cp ratio were calculated mathematically. The results were showed highly significant decreasing(p<0.05) in T-AOC and Zinc concentration in stages (C+D) subgroup compared to (A+B) and control group. Both Ceruloplasmin and copper were found markedly increased in stages (C+D) compared to (A+B) stages and control group. Cu/Zn ratio was increased significantly in advanced stages and controls while Cu/Cp ratio was markedly decreased in advanced stages compared to early stages and controls. In conclusion the results of present study suggests that TAO-C and/or Cp and its related elements are monitoring factors and prognostic indicators could be valuable during the treatment with adjuvant regimen for sporadic colorectal cancer patients.